{
    "clinical_study": {
        "@rank": "26919", 
        "acronym": "IAPREC", 
        "arm_group": [
            {
                "arm_group_label": "intensive controle group", 
                "arm_group_type": "Experimental", 
                "description": "the end point in this group was to maintain the systolic blood pressure (SBP)  between 110 and 120 mmHg using continuous Isosorbide Dinitrate (RISORDON) perfusion associated, if needed, with Labetalol (TRANDATE) continuous perfusion."
            }, 
            {
                "arm_group_label": "standard control group", 
                "arm_group_type": "Active Comparator", 
                "description": "the end point in these group was to maintain the systolic blood pressure between 120 and 140 mmHg using a continuous perfusion of Isosorbide Dinitrate (RISORDON) or other drugs depending on the physician choice."
            }
        ], 
        "brief_summary": {
            "textblock": "The intensive arterial pressure control in acute coronary syndrome (ACS) during the first 24\n      hours can improve the prognosis in the short and long term.\n\n      We confront two treatment strategies (standard and intensive treatment) to evaluate their\n      superiority in the treatment of acute coronary syndrome."
        }, 
        "brief_title": "Intensive Arterial Pressure Control in Acute Coronary Syndrome", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Acute coronary syndrome is often associated with arterial pressure elevation which are\n      deleterious for the heart and needs urgent intervention to lower the blood pressure to the\n      required values, however there is no clear recommendations concerning the treatment\n      intensity in this situation.\n\n      The investigators know that high arterial pressure increases the oxygen myocardial\n      consumption and it is deleterious in acute coronary syndrome, so , it is logical to reduce\n      intensively this pressure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute Coronary Syndrome\n\n        Exclusion Criteria:\n\n          -  SBP under 100 mmHg or hemodynamic instability\n\n          -  complicated ACS (arrythmias, atrio-ventricular block, shock, tamponade...) or ST\n             elevation myocardial infarction (STEMI)\n\n          -  contre indications of beta blockers (asthma, chronic obstructive pulmonary disease\n             (COPD), glaucoma, prostatic disorders...)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135315", 
            "org_study_id": "IAPREC"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "intensive controle group", 
                    "standard control group"
                ], 
                "description": "continuous infusion of Isosorbide dinitrate (40 mg per 40 ml) depending on the systolic blood pressure value.\nSBP: under 120 mmHg : no drug SBP: 120 to 130: 1 mg per hour SBP: 130 to 140: 2 mg per hour SBP: 140 to 150: 3 mg per hour SBP: 150 to 160: 4 mg per hour SBP: above 160 mmHg : 6 mg per hour", 
                "intervention_name": "Isosorbide Dinitrate", 
                "intervention_type": "Drug", 
                "other_name": "RISORDON"
            }, 
            {
                "arm_group_label": "intensive controle group", 
                "description": "continuous infusion of Labetalol (TRANDATE) is used if the arterial pressure objectives are not reached with the Isosorbide Dinitrate alone.\nDilution Labetalol: 200 mg in 40 ml: 4mg per ml SBP: under 110 mmHg: no drug SBP: 110 to 130: 4 mg per hour SBP: 130 to 150: 8 mg per hour SBP: above 150 mmHg: 16 mg per hour", 
                "intervention_name": "Labetalol", 
                "intervention_type": "Drug", 
                "other_name": "TRANDATE"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Labetalol", 
                "Isosorbide Dinitrate", 
                "Isosorbide-5-mononitrate", 
                "Isosorbide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Acute Coronary Syndrome, arterial pressure", 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "description": "official department website", 
            "url": "http://www.urgencemonastir.com"
        }, 
        "location": {
            "contact": {
                "email": "semir.nouira@rns.tn", 
                "last_name": "Nouirahead of departement", 
                "phone": "216073532014"
            }, 
            "contact_backup": {
                "email": "semir.nouira@rns.tn", 
                "last_name": "Fattouma Bourguiba University Hospital", 
                "phone": "+216 73 106 085"
            }, 
            "facility": {
                "address": {
                    "city": "Monastir", 
                    "country": "Tunisia", 
                    "zip": "5000"
                }, 
                "name": "university of Monastir"
            }, 
            "investigator": {
                "last_name": "semir nouira, professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Tunisia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interest of an Intensive Arterial Pressure Control in Acute Coronary Syndrome", 
        "overall_contact": {
            "email": "semir.nouira@rns.tn", 
            "last_name": "Semir Nouira, Professor", 
            "phone": "+21673532014"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Tunisia: Office of Pharmacies and Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "mortality at one month.", 
                "measure": "mortality", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "mortality at six months.", 
                "measure": "mortality", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "mortality at one year.", 
                "measure": "mortality", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135315"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Monastir", 
            "investigator_full_name": "Nouira", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "chest pain recurrence was noted during patients hospital stay in emergency or cardiology departments", 
                "measure": "recurrence of chest pain", 
                "safety_issue": "No", 
                "time_frame": "during hospital admission"
            }, 
            {
                "description": "ACS complications such as cardiogenic shock, arrythmias, conduction troubles... were noted during patients hospital stay in emergency or cardiology departments", 
                "measure": "Acute Coronary Syndrome complication", 
                "safety_issue": "No", 
                "time_frame": "during hospital admission"
            }, 
            {
                "description": "acts of revascularisation were noted for all patients during their hospital stay and over a one year followup period", 
                "measure": "revascularisation", 
                "safety_issue": "No", 
                "time_frame": "at hospital admission and during the followup period of one year"
            }, 
            {
                "description": "stroke events were noted for patients during the followup period of one month, six months and one year.", 
                "measure": "stroke", 
                "safety_issue": "No", 
                "time_frame": "1 month, 6 months and 1 year period"
            }, 
            {
                "description": "non cardiac deaths were investigated during the one year followup period.", 
                "measure": "non cardiac deaths", 
                "safety_issue": "No", 
                "time_frame": "over the 1 year followup period"
            }
        ], 
        "source": "University of Monastir", 
        "sponsors": {
            "collaborator": {
                "agency": "Emergency", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Monastir", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}